NCT03342261

Benefit of DAA Therapy in HCV Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia

Benefit of Direct-acting Antiviral Therapy in Hepatitis C Virus (HCV) Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 47 (actual)
• Sponsor: Hospices Civils de Lyon · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Mixed cryoglobulinemia (MC) is common in patients with chronic hepatitis C virus (HCV) infection. Direct-acting antiviral (DAA) regimens are today very effective with sustained virological response rates (SVR12) above 90%. The objective of this study was to investigate the impact of DAA therapy on cryoglobulin clearance in patients with HCV-associated MC.

Detailed description

We focused on HCV patients with or without HIV with MC who had at least one cryoglobulin level assessment before and after DAA therapy and investigated the impact of DAA therapy on cryoglobulin clearance.

Conditions

• Hepatitis C, Chronic
• Mixed Cryoglobulinemia

Interventions

Type	Name	Description
DRUG	DAA treatment	Patients were treated with direct-acting antiviral (DAA) treatment for 12 or 24 weeks

Timeline

• Start date: 2017-03-01
• Primary completion: 2017-11-01
• Completion: 2017-11-01
• First posted: 2017-11-14
• Last updated: 2017-11-14

Locations

1 site across 1 country: France